19 AugNew Frontiers of Genomic Medicine


The issue surrounding gene therapy and genomic modification has been a hot topic for some time. The thought of using gene editing to replace faulty DNA with healthy DNA in patients with Genomic disorders was first presented in 1972 by …

Read More
Sientra Inc. Update

03 JulSientra Inc. (SIEN): Bound for a Significant Move. Our Price Target Increased.


Sientra Inc. (SIEN) 12 – 18m Price Target: $38.00 Price: $19.90 Upside: 90% We first wrote about Sientra Inc. on …

To access this post, you must purchase Membership.
Read More

28 JunTeva Pharmaceuticals (TEVA): Bullish Narrative Continues, Our PT Stands


Teva Pharmaceutical Inc. (TEVA) 12 – 18m Price Target: $40.00 Price: $23.75 Upside: 68% On March 11, 2018, we published …

To access this post, you must purchase Membership.
Read More

06 JunSientra Inc. (SIEN): Acquisition around the corner?


Since its inception, Sientra was quickly able to establish itself as one of the best providers of breast implants and tissue…

To access this post, you must purchase Membership.
Read More

11 MarTEVA PHARMACEUTICAL INC. (TEVA): Possibly the most undervalued global pharmaceutical company?


BUSINESS OVERVIEW Teva pharmaceuticals (TEVA) is a pharmaceutical company that operates globally, with significant foothold in United States, Europe, and various…

To access this post, you must purchase Membership.
Read More

09 OctCohBar Inc. (CWBR): Battle with Time and Aging


CohBar inc. (CWBR) is known as the leader in the emerging field of mitochondria-based therapeutics for treatment of age-related diseases. Their main focus…

To access this post, you must purchase Membership.
Read More

18 AugSientra, Inc. (SIEN): Turn around story near completion


Sientra, Inc. is a medical aesthetics company, which engages in developing and commercializing plastic surgery implantable devices. Its products include breast…

To access this post, you must purchase Membership.
Read More